A Breakthrough Device Discovered to Treat Major Depressive Disorder (MDD)

Sooma discovered a novel depression therapy for the treatment of people affected by major depressive disorder (MDD). It is a portable, patient-administered neuromodulation device.

Sooma Depression Therapy will be an new treatment option for miilions of people suffering with depression in U.S. It is estimated that 21 million people in the United States suffer from at least one episode of major depression each year. The device enables fast, efficient and affordable treatment on a larger scale. The device stimulates targeted areas of the brain with a weak electrical current that significantly improves symptoms of depression.

Somatic depression therapy has the potential to significantly improve the lives of people with depression by providing simple, accessible and affordable treatment, allowing a flexible treatment option for those who have failed medication or have limited access to psychotherapy.  

Soma depression therapy is an effective first-line depression treatment option used by thousands of patients in more than 30 countries each year. The treatment is painless, does not contain drugs and is always prescribed by a doctor. Treatment consists of daily 30-minute treatment sessions and lasts at least three weeks. It can also be used as a standalone treatment or as an adjunct to other treatments, such as medications, without the risk of dangerous drug interactions.

US (FDA) grants Breakthrough Device Designation for the Sooma Depression Therapy.